Cannabis and tumour markers: what the early evidence shows
Medical oncologists use tumor markers as one part of assessing cancer, alongside imaging, pathology, symptoms and blood tests. These markers are proteins or other substances produced by tumour cells, normal tissues or the body’s response to disease. Their value depends on the cancer type: some are useful for tracking progression, while others have limited value outside specific situations. A rising or falling result therefore does not automatically mean that a tumour has grown or shrunk.
The role of cannabis in reducing tumor markers remains uncertain and should not be confused with treating the cancer itself. Laboratory and animal research has produced interesting signals, but clinical studies in people are limited and usually focus on pain, nausea, sleep or quality of life. Cannabis oils may support symptom management for some patients, yet current evidence does not establish that they reliably lower tumour markers, destroy tumours or improve survival. This distinction is central to the personalised consultations and application reviews offered by CBD International.
Understanding what a tumour marker can show
Common markers include PSA for prostate cancer, CEA for several gastrointestinal cancers, CA 19-9 for pancreatic and biliary cancers, CA 125 for ovarian cancer and AFP for some liver cancers. Each has important limitations. PSA can rise because of benign prostate enlargement, while CA 19-9 may increase during pancreatic inflammation. Infection, recent surgery, liver or kidney dysfunction, medication and laboratory testing methods can also influence results.
For this reason, oncologists rarely interpret one result in isolation. A sustained trend over time may provide more information than a single reading, particularly when it agrees with imaging and changes in symptoms. Patients considering cannabis because a marker has changed should ask what the marker measures, whether other signs suggest progression and whether the result might have been affected by treatment or an unrelated condition. Cannabis should never be used to delay investigation of an unexplained rise or decline.
What laboratory research suggests
Cannabinoids act on biological systems including the cannabinoid receptor type 1, found in the central nervous system, and cannabinoid receptor type 2, which is expressed by many immune and other cells. In cell cultures, CBD and THC have produced effects on cell-cycle regulation, apoptosis, inflammation, invasion and blood-vessel formation. Some combinations have also reduced the viability of cultured cancer cells under particular laboratory conditions.
These findings generate useful hypotheses, but they do not demonstrate an anti-cancer effect in patients. Concentrations applied to isolated cells may be much higher than concentrations safely achieved in blood. Cell cultures also lack an intact immune system, blood supply, digestive system and normal hormonal environment. Different cannabis oils contain varying amounts of THC, CBD and other cannabinoids, so a laboratory result cannot simply be transferred to a commercial product or an individual treatment plan. The distance between laboratory signals and meaningful clinical outcomes remains substantial.
Evidence from people with cancer
Direct research on cannabis and tumour markers consists mainly of individual case reports, small observational studies and laboratory work, rather than robust randomised trials. These reports can reveal patterns worth investigating, but they cannot reliably estimate how often cannabis helps. Improvements may reflect changes in inflammation, liver function, medication, appetite or the natural course of disease rather than a direct tumour response.
Clinical trials of cannabinoid medicines have more often measured symptom relief than tumour shrinkage or marker reduction. A large randomised study involving nabiximols, a THC and CBD oromucosal spray, focused on pain in advanced cancer and did not establish an anti-tumour effect. Some patients using cannabis also describe better sleep, less nausea or reduced distress, which can improve daily functioning without changing the cancer itself. For patients focused on analgesic use, transitioning from painkillers should involve a prescriber, as stopping opioid medicines suddenly can cause withdrawal and other risks.
Cannabis oils and different administration methods
“Cannabis oil” describes products that may differ considerably in composition. Some are CBD-dominant, while others contain THC or a balanced THC and CBD formulation. The stated cannabinoid content, carrier oils, extraction method and recommended delivery route all influence exposure. CBD International’s approach of reviewing the person’s condition, existing medicines and treatment goals is therefore more informative than choosing solely from a product description.
Oral drops, capsules and sprays undergo digestion and first-pass metabolism, producing slower but potentially longer-lasting effects. Sublingual preparations are absorbed under the tongue, while rectal administration can be considered when swallowing is difficult. Information on oral pain relief options can help patients compare administration methods with their prescribing clinician. No route has been proven to reduce tumour markers. Symptom relief and disease modification are separate outcomes, and a formulation that suits one patient may be inappropriate for another because of potency, side effects or medical interactions.
Australian access, regulation and practical considerations
Australia’s Therapeutic Goods Administration regulates medicinal cannabis products and their supply through the Australian Register of Therapeutic Goods. Some hemp-derived CBD products containing low levels of THC are sold as food supplements, but legal sale does not mean they are approved medicines for cancer or tumour-marker reduction. Patients in Sydney, Melbourne, Brisbane and other cities commonly access medicinal cannabis through a participating clinic, medical assessment, prescription and licensed dispensing pharmacy. Costs are generally paid privately because medicinal cannabis is not routinely subsidised through the Pharmaceutical Benefits Scheme.
Australian customs rules create another important layer. International prescriptions and online orders do not automatically authorise the import of cannabis products. Personal imports may require approval through the Office of Scientific and Technical Information, together with the relevant state or territory requirements, and a product must be lawfully importable and supplied for lawful use. THC content also matters locally: driving laws, workplace policies and fitness-to-drive requirements vary across states and territories. Patients should obtain current advice before travelling with cannabis medicines, apply for an appropriate product or use a prescription obtained through an authorised Australian pathway.
Integrating cannabis with cancer care
Cannabis is best considered within a broader supportive-care plan and should be discussed with the treating oncologist as well as the clinician prescribing the cannabis product. CBD and THC may interact with medicines used in cancer care, anticoagulants, some antidepressants, anticonvulsants and sedatives. Combining cannabis with opioids can increase drowsiness, dizziness and impairment, while THC may cause anxiety, tachycardia or altered perception. Baseline liver and kidney function, other medicines and the intended dose should be reviewed, with follow-up arranged as needed.
For patients already receiving opioid therapy, background information on cannabis alongside opioid therapy provides a useful starting point for a supervised discussion about pain, function and medication use. Reduced opioid requirements may be an important supportive outcome, but it is not evidence that the tumour has responded. Patients can record pain scores, sleep, nausea, medication use and adverse effects while oncology teams continue to track appropriate tumour markers, imaging and disease symptoms. Any decision to start, change or stop treatment should remain part of the coordinated clinical plan.
CBD International provides information on cannabis and CBD oil formulations, administration methods, consultations, application review and ongoing support for patients and families. Prospective patients can compare the available products with the route of administration, cannabinoid profile and supportive needs discussed during their consultation.
The most responsible first step is to contact the consultation team about eligibility, product selection and lawful Australian access, while keeping the treating oncologist and prescribing clinician informed.